DASH Lowers Average Blood Pressure, Not BP Variability

DASH lowers the average. It does not quiet the swings.

The DASH diet remains one of the best-supported eating patterns for lowering average blood pressure. But average pressure and blood pressure variability are different measurements, and a recent reanalysis of the original DASH trials found that DASH did not significantly reduce variability after accounting for its effect on mean blood pressure.

That distinction matters if you use home readings, ambulatory monitoring, or a connected cuff and wonder why a better weekly average can coexist with uneven day-to-day numbers. Diet can improve the average without changing the biological systems that drive short-term and longer-term fluctuations.

The evidence does not make DASH less useful. It makes the claim more precise: use DASH to lower mean blood pressure. Do not assume it stabilizes blood pressure variability, or BPV, as a separate treatment target.

What the DASH reanalysis found

In a post-hoc pooled reanalysis of the landmark DASH and DASH-Sodium randomized trials, Zou et al. (2026) examined both average blood pressure and BPV over interventions lasting 8 to 11 weeks. The investigators used variance independent of the mean, or VIM, a calculation designed to separate variability from the average reading. That choice matters: a person whose blood pressure falls may appear less variable under simpler measures even when the underlying swings have not changed.

DASH did not significantly change week-to-week office systolic BPV. The VIM difference was 0.49, with a 95% confidence interval from -0.05 to 1.03. The result for 24-hour ambulatory systolic BPV was also nonsignificant: VIM difference 0.37, 95% CI -0.13 to 0.87. Because both confidence intervals cross zero, these data do not support a BPV-lowering effect over the trial period.

Reducing sodium also showed no independent effect on BPV, and the analysis found no sodium-by-diet interaction. The investigators interpreted DASH's blood-pressure benefit as a mean-pressure effect rather than a variability effect. That is narrower than saying DASH has only one cardiovascular mechanism, but it is the correct conclusion for these measured outcomes and this time frame.

A Japanese feasibility trial points in the same direction, with much less certainty. In Umemoto et al. (2022), Japanese adults with untreated high-normal blood pressure or stage I hypertension received a Japanese cuisine-based DASH pattern, with or without fish oil, or usual diet. Across a two-month intervention and four-month follow-up, the diet arms did not significantly reduce morning or evening home BPV measured by standard deviation and coefficient of variation.

It would be a mistake to call that cross-cultural confirmation. The study was a single-center feasibility trial, was not powered for BPV, and one intervention arm included fish oil. Any small BPV trend in that arm cannot be assigned to the diet alone. Its null result is compatible with the larger DASH reanalysis, but it could also reflect limited precision.

Why variability may matter—and why the evidence needs restraint

BPV describes changes in pressure across beats, hours, days, or clinic visits. These are not interchangeable phenomena. A rise when you climb stairs is expected. Repeated large or poorly regulated fluctuations may reflect impaired vascular buffering, altered baroreflex function, autonomic dysregulation, medication timing, measurement conditions, or illness.

Lee et al. (2022) used beat-to-beat recordings to distinguish healthy blood-pressure complexity from pathological instability. Their work links reduced complexity with markers of vascular aging and stroke risk, and frames arterial compliance and baroreflex integrity as important regulators of blood-pressure dynamics. It provides a useful physiological model, not proof that changing any one BPV metric prevents stroke.

Observational studies add clinical context. In people with resistant hypertension, He et al. (2025) reported correlations between BPV, heart-rate variability, and renal, cardiac, and vascular measures of target-organ damage. The cross-sectional design cannot establish whether variability caused the damage, resulted from it, or traveled with other features of severe hypertension.

Similarly, Candemir et al. (2026) found that 24-hour in-hospital BPV predicted length of stay and adverse events among patients admitted with acute decompensated heart failure. That population is far sicker than a typical person checking morning pressure at home. The finding supports BPV's prognostic relevance in an acute-care setting; it does not create a home-monitoring threshold or show that lowering variability improves outcomes.

The broader BPV-outcomes literature also has technical traps. Analyses can confuse variability with higher mean blood pressure if they do not adjust appropriately. Adjusting daytime variability with a 24-hour average can partly turn BPV into a proxy for nighttime pressure. Studies that calculate variability from later follow-up readings and label it a baseline predictor can introduce immortal-time bias. BPV is worth studying, but its independent contribution to cardiovascular risk remains harder to quantify than many headlines imply.

Why diet might need more time to affect BPV

The DASH reanalysis answers a specific question: whether the intervention changed measured BPV over 8 to 11 weeks. It does not rule out a slower diet-to-vascular-health pathway. Arterial stiffness and vascular remodeling may change over months or years, not several weeks.

That possibility has indirect support from Lobene et al. (2022), a cross-sectional study of healthy young adults. Greater adherence to healthy dietary patterns was associated with lower diastolic pressure and lower augmentation index, a surrogate for wave reflection and arterial stiffness. The study did not measure BPV directly and cannot show that diet caused the lower augmentation index. Fitness, metabolic health, and other unmeasured differences could explain part or all of the association.

So the fair reading is neither "diet can never affect BPV" nor "healthy eating eventually must stabilize BPV." Randomized evidence currently shows no specific short-term BPV benefit from DASH or the Japanese DASH-style feasibility intervention. Longer, adequately powered trials that measure both vascular function and clearly defined BPV outcomes would be needed to test the structural hypothesis.

Exercise has a more direct link to autonomic regulation

For BPV specifically, exercise has a more plausible evidence base than diet because it directly trains systems involved in short-term cardiovascular regulation. A 2024 systematic review and meta-analysis by Abidi et al., covering 15 studies in people with hypertension, found that exercise training improved cardiac autonomic modulation. That does not prove that every exercise program lowers every form of BPV, but it targets a relevant pathway more directly than changing food composition alone.

Combined lifestyle programs still matter greatly for average pressure. In the TRIUMPH randomized trial, intensive lifestyle modification reduced blood pressure in patients with resistant hypertension. The intervention combined diet, structured exercise, and weight management, so it cannot identify which component produced the change or answer whether BPV changed.

A related trial by Hinderliter et al. (2021) found that DASH plus behavioral weight management could reduce the need for guideline-directed antihypertensive medication in adults with untreated hypertension. Again, that is a mean-blood-pressure result, not evidence for BPV control.

Passive heating remains an interesting but preliminary adjunct. A 2023 systematic review found that heating protocols acutely altered cardiovascular autonomic measures in healthy adults. Responses varied by protocol: whole-body heating often reduced vagal modulation, while local heating and sauna bathing appeared to increase it in some studies. Acute autonomic changes are not proof of sustained BPV improvement, and sauna is not a substitute for hypertension treatment.

What to do with a variable home blood-pressure log

First, protect the measurement. Use a validated upper-arm cuff, a consistent time of day, seated rest, repeated readings, and a record of exercise, caffeine, alcohol, illness, poor sleep, and medication timing. A messy measurement routine can manufacture drama from ordinary physiology.

• Use DASH if your goal is a lower average blood pressure.
• Include regular exercise for cardiovascular fitness and autonomic health.
• Do not try to self-treat high variability with supplements, sodium extremes, or aggressive heat exposure.
• Discuss persistently erratic readings, very high readings, fainting, chest symptoms, or medication questions with a clinician.

DASH has earned its place in blood-pressure care. The current trials simply do not show that it also reduces blood-pressure variability.

The practical lesson is simple: the average on your cuff and the scatter around it answer different questions. DASH improves the first. For the second, exercise and clinical evaluation have a stronger rationale than a dietary promise the trials have not delivered.